Literature DB >> 15980973

Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study.

Daniel A Hamstra1, Bradford A Moffat, Daniel E Hall, John M Young, Timothy J Desmond, Julie Carter, Dennis Pietronigro, Kirk A Frey, Alnawaz Rehemtulla, Brian D Ross.   

Abstract

Solvent facilitated perfusion (SFP) has been proposed as a technique to increase the delivery of chemotherapeutic agents to tumors. SFP entails direct injection of the agent into the tumor in a water-miscible organic solvent, and because the solvent moves easily through both aqueous solutions and cellular membranes it drives the penetration of the solubilized anticancer agent throughout the tumor. To test this hypothesis, we compared the pharmacokinetics (PK) of 14C-labeled 1,3-bis-chlorethyl-1-nitrosourea (BCNU) in intra-cerebral 9L rat gliomas after intravenous (IV) infusion in 90% saline--10% ethanol or direct intratumoral (IT) injection of 14C-BCNU in 100% ethanol (DTI-015). Treatment with DTI-015 yielded a peak radioactive count (Cmax) for the 14C label that was 100-1000 fold higher in the tumor than in all other tissues in addition to a concentration in the tumor that was 100-fold higher than that achieved following IV infusion of 14C-BCNU. Pathologic and auto-radiographic analysis of tissue sections following IT injection of 14C-BCNU in ethanol into either tumor or normal rat brain revealed both an enhanced local volume of distribution and an increased concentration of BCNU delivered to tumor compared to non-tumor bearing brain. To investigate the mechanism behind the SFP of BCNU to the tumor both dynamic contrast and perfusion MRI were performed on 9L tumors before and after treatment and demonstrated a decrease in tumor perfusion following IT injection of DTI-015. Finally, initial PK of patient blood samples following administration of DTI-015 into relapsed high-grade glioma indicated a 20-fold decrease in systemic exposure to BCNU compared to IV infusion of BCNU providing further evidence for the enhanced therapeutic ratio observed for DTI-015.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980973     DOI: 10.1007/s11060-004-5675-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study.

Authors:  B D Ross; Y J Zhao; E R Neal; L D Stegman; M Ercolani; O Ben-Yoseph; T L Chenevert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

2.  A chemical basis for the antitumor activity of chloroethylnitrosoureas.

Authors:  M Colvin; R B Brundrett; W Cowens; I Jardine; D B Ludlum
Journal:  Biochem Pharmacol       Date:  1976-03-15       Impact factor: 5.858

3.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

4.  Intracerebral clysis in a rat glioma model.

Authors:  J N Bruce; A Falavigna; J P Johnson; J S Hall; B D Birch; J T Yoon; E X Wu; R L Fine; A T Parsa
Journal:  Neurosurgery       Date:  2000-03       Impact factor: 4.654

5.  Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.

Authors:  Alessandro Olivi; Stuart A Grossman; Stephen Tatter; Fred Barker; Kevin Judy; Jeffrey Olsen; Jeffrey Bruce; Dana Hilt; Joy Fisher; Steve Piantadosi
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

6.  Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015.

Authors:  William J Bodell; Donald D Giannini; Saira Singh; Dennis Pietronigro; Victor A Levin
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

7.  The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in man and animals.

Authors:  V T DeVita; C Denham; J D Davidson; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1967 Jul-Aug       Impact factor: 6.875

Review 8.  Primary brain tumours in adults.

Authors:  Anthony Behin; Khe Hoang-Xuan; Antoine F Carpentier; Jean-Yves Delattre
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

9.  Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.

Authors:  T L Chenevert; P E McKeever; B D Ross
Journal:  Clin Cancer Res       Date:  1997-09       Impact factor: 12.531

10.  Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.

Authors:  B R O'Driscoll; P S Hasleton; P M Taylor; L W Poulter; H R Gattameneni; A A Woodcock
Journal:  N Engl J Med       Date:  1990-08-09       Impact factor: 91.245

View more
  8 in total

1.  Mathematical Modelling of Convection Enhanced Delivery of Carmustine and Paclitaxel for Brain Tumour Therapy.

Authors:  Wenbo Zhan; Davis Yohanes Arifin; Timothy Ky Lee; Chi-Hwa Wang
Journal:  Pharm Res       Date:  2017-02-02       Impact factor: 4.200

2.  Effects of solvent used for fabrication on drug loading and release kinetics of electrosprayed temozolomide-loaded PLGA microparticles for the treatment of glioblastoma.

Authors:  Daniel A Rodriguez de Anda; Nareg Ohannesian; Karen S Martirosyan; Sue Anne Chew
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2019-02-15       Impact factor: 3.368

3.  Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol).

Authors:  William J Bodell; Alexander P Bodell; Donald D Giannini
Journal:  Neuro Oncol       Date:  2006-10-03       Impact factor: 12.300

4.  Mechanism of low-frequency ultrasound in opening blood-tumor barrier by tight junction.

Authors:  Xiuli Shang; Ping Wang; Yunhui Liu; Zhen Zhang; Yixue Xue
Journal:  J Mol Neurosci       Date:  2010-09-18       Impact factor: 3.444

5.  Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model.

Authors:  Grace Y Kim; Betty M Tyler; Malinda M Tupper; Jeffrey M Karp; Robert S Langer; Henry Brem; Michael J Cima
Journal:  J Control Release       Date:  2007-08-15       Impact factor: 9.776

6.  Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.

Authors:  Michael D Jenkinson; Trevor S Smith; Brian Haylock; David Husband; Aditya Shenoy; Sobhan Vinjamuri; Carol Walker; Denis Pietronigro; Peter C Warnke
Journal:  J Neurooncol       Date:  2010-01-10       Impact factor: 4.130

7.  Intratumoral injection of cisplatin in various concentrations of ethanol for cisplatin-resistant lung tumors.

Authors:  Qi Niu; Wei Wang; Qian Li; Yong Li; Douglas M Ruden; Fenghua Wang
Journal:  Mol Clin Oncol       Date:  2014-04-14

8.  Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV Non-Small Cell Lung Cancer.

Authors:  Qi Niu; Wei Wang; Qian Li; Yong Li; Douglas M Ruden; Baoming He
Journal:  Transl Oncol       Date:  2014-03-04       Impact factor: 4.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.